Yahoo Sports College Expert Cassandra Negley takes you through the dominant Final Four performance of the Arizona Wildcats and Aari McDonald against the top-seeded Connecticut Huskies.
Yahoo Sports College Expert Cassandra Negley takes you through the dominant Final Four performance of the Arizona Wildcats and Aari McDonald against the top-seeded Connecticut Huskies.
The "Multi Cooker Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
N'DJAMENA (Reuters) - Thousands of people gathered at the main square in Chad's capital N'Djamena on Friday to pay their respects to the late President Idriss Deby, who was killed while leading his troops against a rebel offensive on Monday. French President Emmanuel Macron, Guinean President Alpha Conde and several other African leaders were expected to attend the funeral, despite rebel warnings they should not attend for security reasons. Deby ruled Chad for more than 30 years and was one of Africa's wiliest political survivors, holding on to power despite rebellions that reached as far as his palace gates.
(Bloomberg) -- Gold is headed for a third straight weekly gain as bond yields and the dollar continued their downtrend after surging at the start of the year.Applications for U.S. state unemployment insurance unexpectedly plunged to a fresh pandemic low, weighing on demand for haven assets and pushing bullion down from the highest in nine weeks. The metal did trim its loss after Bloomberg reported President Joe Biden would propose almost doubling the capital gains tax for wealthy individuals, which hammered U.S. stocks.Gold is heading for a small weekly gain as U.S. bond yields continue to trend lower after rising in the first quarter, making the non-interest bearing metal more attractive. Also adding support is weakness in the dollar and a revival in consumer demand in Asia. Shipments from Switzerland to India and China rose last month, indicating renewed buying by the top consumers after a year on the sidelines.That’s unlikely to send prices higher in the long term though, for which gold relies on investment demand. Outflows from exchange-traded funds -- which were crucial to bullion’s rally to a record price in August -- have slowed but not stopped in recent weeks, while net-bullish bets on the metal by hedge funds on the Comex remain low.Spot gold was little changed at $1,785.08 an ounce at 9:55 a.m. in London and is on track for 0.5% gain this week. Prices dropped 0.6% on Thursday after earlier rising to $1,797.93, the highest level since Feb. 25. Silver declined and platinum advanced, while palladium steadied after surging to a record this week. The Bloomberg Dollar Spot Index retreated 0.3% is poised for a third weekly decline.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
The "Global Construction Dumper Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.
Dublin, April 23, 2021 (GLOBE NEWSWIRE) -- The "Next Generation Cancer Diagnostics Market Research Report by Technology, by Cancer Type, by Function, by Application - Global Forecast to 2025 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering. The Global Next Generation Cancer Diagnostics Market is expected to grow from USD 5,693.79 Million in 2020 to USD 15,738.27 Million by the end of 2025.Cumulative Impact of COVID-19:COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.FPNV Positioning Matrix:The FPNV Positioning Matrix evaluates and categorizes the vendors in the Next Generation Cancer Diagnostics Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.Competitive Strategic Window:The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.The report answers questions such as:1. What is the market size and forecast of the Global Next Generation Cancer Diagnostics Market?2. What are the inhibiting factors and impact of COVID-19 shaping the Global Next Generation Cancer Diagnostics Market during the forecast period?3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Next Generation Cancer Diagnostics Market?4. What is the competitive strategic window for opportunities in the Global Next Generation Cancer Diagnostics Market?5. What are the technology trends and regulatory frameworks in the Global Next Generation Cancer Diagnostics Market?6. What are the modes and strategic moves considered suitable for entering the Global Next Generation Cancer Diagnostics Market?Key Topics Covered: 1. Preface2. Research Methodology3. Executive Summary3.1. Introduction3.2. Market Outlook3.3. Cancer Type Outlook3.4. Technology Outlook3.5. Function Outlook3.6. Application Outlook3.7. Geography Outlook3.8. Competitor Outlook4. Market Overview4.1. Introduction4.2. Cumulative Impact of COVID-195. Market Insights5.1. Market Dynamics5.1.1. Drivers18.104.22.168. Rising incidence of oncology diseases22.214.171.124. Significantly decreasing cost of genetic sequencing126.96.36.199. Benefits of cluster chip technology and applications of CTC in cancer management5.1.2. Restraints188.8.131.52. Need for expensive laboratory set-up184.108.40.206. Insufficient reimbursement policies for innovative technologies5.1.3. Opportunities220.127.116.11. Government support in a number of research projects in oncology and preventative diagnosis18.104.22.168. Potential CTC enumeration sectors to monitor tumorigenesis5.1.4. Challenges22.214.171.124. Shortage of helium and increased cost of diagnostic imaging systems5.2. Porters Five Forces Analysis6. Global Next Generation Cancer Diagnostics Market, By Technology6.1. Introduction6.2. DNA Microarrays6.3. Lab-on- a- chip & Reverse Transcriptase-PCR6.4. Next Generation Sequencing6.5. Protein Microarrays6.6. qPCR & Multiplexing7. Global Next Generation Cancer Diagnostics Market, By Cancer Type7.1. Introduction7.2. Breast Cancer7.3. Cervical Cancer7.4. Colorectal Cancer7.5. Lung Cancer8. Global Next Generation Cancer Diagnostics Market, By Function8.1. Introduction8.2. Cancer Screening8.3. Companion Diagnostics8.4. Prognostics8.5. Risk Analysis8.6. Therapeutic Monitoring9. Global Next Generation Cancer Diagnostics Market, By Application9.1. Introduction9.2. Biomarker Development9.3. CTC Analysis9.4. Epigenetic Analysis9.5. Genetic Analysis9.6. Proteomic Analysis10. Americas Next Generation Cancer Diagnostics Market11. Asia-Pacific Next Generation Cancer Diagnostics Market12. Europe, Middle East & Africa Next Generation Cancer Diagnostics Market13. Competitive Landscape13.1. FPNV Positioning Matrix13.2. Market Ranking Analysis13.3. Market Share Analysis13.4. Competitor SWOT Analysis13.5. Competitive Scenario14. Company Usability Profiles14.1. Abbott Laboratories14.2. Adaptive Biotechnologies Inc.14.3. Agendia Nv14.4. Agilent Technologies, Inc14.5. Akadeum Life Sciences14.6. Almac Group14.7. Ambry Genetics14.8. Becton, Dickinson And Co.14.9. Biological Dynamics Inc.14.10. Castle Biosciences Inc.14.11. Danaher Corporation14.12. Exosome Diagnostics, Inc.14.13. F. Hoffmann-La Roche Ltd14.14. GE Healthcare14.15. Genomic Health, Inc.14.16. Hologic, Inc14.17. Illumina, Inc.14.18. Janssen Global Services, LLC14.19. Koninklijke Philips N.V.14.20. Myriad Genetics, Inc.14.21. Novartis AG14.22. Opko Health, Inc.14.23. Perkin Elmer, Inc.14.24. Qiagen N.V.14.25. Sysmex Corporation14.26. Thermo Fisher Scientific, Inc. For more information about this report visit https://www.researchandmarkets.com/r/5aee8w CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Hiab and FSP Ltd have reached an agreement about the surface treatment operations in Hiab’s Stargard multi-assembly unit in Poland.
A deluge of new orders swept through British businesses in April as the country lifted some of its COVID-19 restrictions, according to a survey on Friday that pointed to a rapid rebound for the pandemic-hit UK economy. The preliminary "flash" reading of the UK Composite Purchasing Managers' Index (PMI) rose to 60.0 in April from 56.4 in March, its highest reading since November 2013. Clothing retailers able to sell online benefitted especially as consumers got ready to venture out after being locked down for much of the past year.
Deutsche Bank has reached a pay deal with staff at call centres who have been on strike, two people with knowledge of the matter said on Friday. The agreement brings to an end a months-long labour dispute involving about 650 staff in Berlin and Essen at the call centre unit DB Direkt. The deal envisages a 13th month of pay, a one-time payment and a pay increase, the people said.
Malmö - ZetaDisplay AB (publ) (Nasdaq Stockholm: ZETA) and SNØ, Oslo got first place in the Global Digital Signage Awards, presented at a virtual ceremony on 22nd April 2021. The independent awards recognize outstanding campaigns, creative executions and technical innovations of Digital Signage that elevate the customer experience. SNØ, the world’s largest indoor ski hall near Oslo, Norway and ZetaDisplay won in the “Sports and Entertainment” category. “A big congratulations to the ZetaDisplay Norway team who battled sub-zero temperatures, defying great heights and strict deadlines to deliver a spectacular Digital Signage solution to SNØ,” comments Per Mandorf, President and CEO at ZetaDisplay. The physical signage was accompanied by a transformative and future proofed content strategy to facilitate infotainment through live camera streams from within the arena, live TV and real-time social media and imagery integration, all run from ZetaDisplay’s own CMS platform. About SNØ SNØ is the world’s only year-round arena that unites cross-country skiing, snowboarding, alpine and freeski under the same roof. The centre opened in January 2020 and boasts 36,000m2 of snow-covered slopes and tracks, ideal for downhill skiing, snowboarding and cross-country skiing for beginners and professionals alike. More info at snooslo.no. Malmö, 23rd April 2021 For questions, please contact: Per Mandorf, President & CEOPhone +46 704-25 82 34Email email@example.com Jacob Stjernfält, CFOPhone +46 76-8754177 E-mail firstname.lastname@example.org Daniel Oelker, CCOPhone +46 708-45 80 54 E-mail email@example.com About ZetaDisplay ZetaDisplay acts at the heart of digital transformations in physical environments. We contribute to nudging peoples’ behaviour at the point-of-decision in retail environments, public spaces and workplace environments. Our solutions are known as Digital Signage that we develop and offer as SaaS-solutions. We are a European leader and intend to drive the further consolidation of the market organically and through acquisitions. ZetaDisplay has its head office in Malmö. The company generates revenues of approx. MSEK 450 and employs 200 staff at ten offices in six European countries and the USA. In total, the company handles more than 70,000 installations on over 50 markets. The share is listed on Nasdaq Stockholm [ZETA]. More information at www.ir.zetadisplay.com Attachment 20210423 ZD wins prestigeous Digital Signage Award(Sno) 2021
SIGNATURE BANK ANNOUNCES BOTH EXECUTIVE AND SENIOR MANAGEMENT APPOINTMENTS
VANCOUVER, British Columbia, April 23, 2021 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today reported financial results for the year ended December 31, 2020 (“Fiscal 2020”) and associated Company developments. Unless otherwise noted, all figures are in Canadian currency. “We had a very strong end to our fiscal year and set new records for both the fourth quarter and annual revenue,” said Doug Janzen, Chairman and CEO of Aequus. “2020 gross revenues were $2,592,613 for the year, a 59% increase over Fiscal 2019 revenues of $1,632,524 and Q4 revenues were $851,187 a 59% increase over Q4 2019. Our fourth quarter is traditionally our strongest quarter, and we will work to carry this momentum forward into 2020. We significantly improved on our bottom line as well; the net loss for Fiscal 2020 was $1,045,360, a 66% reduction compared to a net loss of $3,106,104 in Fiscal 2019 and the net loss for Q4 2020 dropped to $165,376 compared to $1,037,354 for the same period in 2019. I am very pleased with our performance in 2020. We have dramatically narrowed our operating losses and continue to close in on our goal of reaching operational break-even. With the recent launch of the EvolveTM and ReviveTM products our focus remains on commercial execution while expanding our existing partnerships to include the acquisition of new products for our growing pipeline. In the next few weeks, we will be submitting the first tranche of information to Health Canada to support the approval of Zimed-PF, a preservative free prescription product for open angle Glaucoma. We are very excited about introducing this product to the Canadian market. We are also encouraged by the pace of negotiations we are having with potential new partners and B2B relationships, despite the challenges associated with the impact of COVID-19 on our partners and customers.” Key 2020 Financial Highlights Highest annual revenue to date, with Fiscal 2020 total revenue of $2.6 million, resulted in an increase of 59% over the $1.6 million in revenue during the year ended December 31, 2019 (“Fiscal 2019”).The three months ended December 31, 2020 (“Fourth Quarter 2020”) had revenues of $851,187, is a 59% increase over the three months ended December 31, 2019 (“Fourth Quarter 2019”).Fiscal 2020 net loss of $1.0 million, a reduction of 66% from the $3.1 million loss in Fiscal 2019, mainly due to higher sales and a temporary reduction in sales expenses during the mandated shutdowns last year.Fourth Quarter 2020 operating loss of $164,750, before other expenses, was 70% less compared to the same quarter in 2019. The Fourth Quarter 2020 net loss of $165,376 was a $871,978 decrease when compared to $1,037,354 net loss in the Fourth Quarter 2019. The change was primarily due to higher sales in 2020 and a $478,940 expense in Q4 2019 related to the impairment of an intangible asset when there was no such expense in Q4 2020. Key 2020 Operational Highlights Commercial Activities On January 10, 2020, the Company advanced the filings for provincial reimbursement in both Quebec and British Columbia for its lead product, PRVistitanTM (Bimatoprost 0.03%). If successful, this additional coverage would advance sales in the second and third largest markets in Canada and would trigger an increase in the percentage of total revenue that Aequus receives from its partner Sandoz.On October 16, 2020, the Company agreed to a contract extension under modified terms for its promotional service agreement with Sandoz Canada Inc. (“Sandoz”) for Tacrolimus IR to December 31, 2021. On October 29, 2020, the Company, together with its partner, Medicom Healthcare Ltd. (“Medicom”), was issued a new Medical Device License for two of three product submissions made for the EvolveTM preservative free dry eye product line, including Daily Intensive Drops and Daily Intensive Gel. Corporate Activities On August 6, 2020, the Company issued 31,250,000 units at a price of $0.08 per unit for aggregate proceeds of $2,500,000. Each unit is comprised of one common share and one-half of one warrant of the Company (each whole common share purchase warrant, a "Warrant"). Each Warrant entitles the holder to purchase one common share at an exercise price of $0.12 for 36 months. The Warrants include an acceleration provision, exercisable at the Company's option, if the Company's daily volume weighted average share price is greater than $0.20 for ten consecutive trading days. 2021 Highlights - Subsequent to December 31, 2020 In February 2021, the Company closed a private placement of 6,666,666 units at a price of $0.15 per unit, for proceeds of $1,000,000 to Marc Lustig, a director of the Company. Each unit shall consist of one common share and one-half warrant. Each warrant shall entitle the holder to purchase one common share at an exercise price of $0.25 for 24 months. In March 2021, the Company elected to exercise its right to trigger an accelerated expiry under the terms of the warrant indenture which governed the Warrants issued under the August 2020 financing, and subsequently issued 12,343,750 shares at $0.12 per share, pursuant to the exercise of certain other common share purchase warrants for net proceeds of $1,481,250. The Company also issued 317,000 shares at $0.22 per share pursuant to the exercise of warrants for net proceeds of $69,740. In March 2021, Aequus launched the newly approved EvolveTM Daily intensive drops and Daily Intensive Gel. Products are sold direct to professionals via a newly created e-commerce platform, www.aequuseyecare.ca. Commercial Update “Despite Covid-19 and significant reductions in rep selling time, -41% in field vs full time deployment, Aequus combined revenues were $2.6 Million, +59% increase compared to Fiscal 2019. Vistitan revenue at +15% and Tacrolimus at +49% showed strong consistent growth as we increased clinic and transplant center penetration respectively. Fourth Quarter 2020 revenues from operations were $851,187, the first time in our Company’s history that we exceeded $750,000 in sales for a single quarter. We’ve successfully executed sales force deployment strategies into key professional areas of Ophthalmology and Transplant across Canada. We’ve used Covid as an opportunity to improve our remote selling capabilities and scale out our technology with video conferencing and professional CRM implementation,” says Grant Larsen, Chief Commercial Officer with Aequus. “Our accelerated ability to adapt to market conditions, and implement digital technology with a scalable platform of assets, is expected to attract international partners looking for rapid access to the Canadian marketplace.” With the addition of business development, medical science liaison and commercial analysis resources in late 2020, our focus is on expanding our product offerings in key strategic areas as well as expanding our established partnerships with Sandoz and Medicom. With a new drug establishment license in Canada, and the demonstrated ability to deliver on promotional partnerships, in-license agreements, we have a flexible business model capable of adapting to many portfolio opportunities. Operating Expenses The Company reported an operating loss before other income of $1,064,989 for Fiscal 2020, an improvement of 60% from the loss before other income of $2,636,560 in Fiscal 2019. The lower loss was primarily due to higher sales and a decrease in research and development expenses. The Fiscal 2020 improvement in loss was offset by higher sales and marketing expenses and a higher interest and accretion expenses recognized in general administration expenses which related to the debenture issued during Fiscal 2019. Sales and marketing costs in Fiscal 2020 were $1,547,773 when compared to $1,857,478 in Fiscal 2019, a reduction of 17% or $309,705. The majority of the reduction related to a decrease in sales activities and reduced work hours due to the COVID-19 pandemic response restrictions which resulted in temporary layoffs, limited travel to customers and reduced in-person meetings. Non-cash expenses for depreciation, amortization and share-based payments in Fiscal 2020 were $91,209 and $150,433 respectively, compared to $189,309 and $82,241 respectively in Fiscal 2019. Research and development project maintenance expenses in Fiscal 2020 were $54,608 when compared to $210,827 in Fiscal 2019, a decrease of 74% or $156,219. The majority of the decrease was attributable to a reduction in consulting and compensation related expenses as we are now focused on revenue generating third-party commercial products as opposed to internal product development programs. General and administration expenses in Fiscal 2020 were $2,055,221 when compared to $2,200,779 in Fiscal 2019, a decrease of 7% or $145,558. The Company’s interest and accretion expenses relating to the convertible debenture issued in May 2019 were $246,753 and $232,433 respectively for Fiscal 2020, compared to $147,478 and $223,428 respectively for Fiscal 2019. The Company recognized cost reductions in Management, wages and related, and travel, and legal and professional fees in Fiscal 2020 which were offset by the increased expenses related to the convertible debenture and interest expenses. ABOUT AEQUUS PHARMACEUTICALS INC. Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) is a growing specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus has grown its sales and marketing efforts to include several commercial products in ophthalmology and transplant. Aequus plans to build on its Canadian commercial platform through the launch of additional products that are either created internally or brought in through an acquisition or license; remaining focused on highly specialized therapeutic areas. For further information, please visit www.aequuspharma.ca. FORWARD-LOOKING STATEMENT DISCLAIMER This release may contain forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “potential” and similar expressions. Forward- looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements include but are not limited to statements relating to: the implementation of our business model and strategic plans; revenue growth trends into the future; expected timing for product launches; the Company’s expected revenues; the regulatory approval of its products; ongoing discussions with current and future partners’ ability to further grow our product portfolio. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making the forward looking statements included in this release, the Company has made various material assumptions, including, but not limited to: obtaining regulatory approvals; general business and economic conditions; the Company’s ability to successfully out license or sell its current products and in-license and develop new products; the assumption that the Company’s current good relationships with third parties will be maintained; the availability of financing on reasonable terms; the Company’s ability to attract and retain skilled staff; market competition; the products and technology offered by the Company’s competitors; the impact of the coronavirus (COVID-19) on the Company’s operations; and the Company’s ability to protect patents and proprietary rights. In evaluating forward looking statements, current and prospective shareholders should specifically consider various factors set out herein and under the heading “Risk Factors” in the Company’s Annual Information Form dated April 28, 2020, a copy of which is available on Aequus’ profile on the SEDAR website at www.sedar.com, and as otherwise disclosed from time to time on Aequus’ SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward looking statements. VistitanTM: Trademark owned or used under license by Sandoz Canada Inc. CONTACT INFORMATION Aequus Investor Relations Email: firstname.lastname@example.org Phone: 604-336-7906
Gal Gadot used her Hollywood starpower to produce "Impact," a new documentary series that follows six women from around the world who made a positive impact on their communities. (April 23)
Major plans for a new 18-room courthouse and police headquarters in the City of London have been given the go-ahead. Eight buildings off Fleet Street are due to be demolished to make way for the new development, dubbed a “Justice Quarter” by the City of London Corporation. The proposals, which include civil, county, and magistrate courts, eight crown courtrooms, and a new base for the City of London Police, were formally approved by the corporation yesterday.
The "Taste Modulators Market Size, Share & Analysis, By Type (Sweet Modulators, Salt Modulator, Fat Modulators), By Application (Food, And Beverages), And By Region, Global Forecast To 2028" report has been added to ResearchAndMarkets.com's offering.
Dublin, April 23, 2021 (GLOBE NEWSWIRE) -- The "Market Spotlight: Renal Disease" report has been added to ResearchAndMarkets.com's offering. This Market Spotlight report covers the Renal Disease market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.Key TakeawaysThe report estimates that in 2018, there were approximately 738.0 million prevalent cases of chronic kidney disease (all stages) in adults aged 20 years and over worldwide. This figure is forecasted to increase to 819.5 million by 2027.The publisher estimates that in 2018, there were 166.6 million cases (22.6%) in stage 1, 185.7 million cases (25.2%) in stage 2, 361.8 million cases (49.0%) in stage 3, 19.0 million cases (2.6%) in stage 4, and 4.8 million cases (0.4%) in stage 5.The approved drugs in the renal disease space focus on a wide variety of targets. The majority of these therapies are administered via the oral route, with the remainder being intravenous, intramuscular, and subcutaneous formulations.The largest proportion of industry-sponsored drugs in active clinical development for renal disease are in Phase I, with only one drug in the NDA/BLA stage.Therapies in the pipeline for renal disease focus on a wide variety of targets. The majority of these therapies are administered orally, with the remainder being intravenous, subcutaneous, hemoperfusion, intramuscular, and topical formulations.High-impact upcoming events for drugs in the renal disease space comprise topline Phase II trial results for suramin and ANG3777; topline Phase III trial results for Sibnayal, veverimer, recAP, and Jardiance; and an expected PDUFA date for Farxiga.The distribution of clinical trials across Phase I-IV indicates that the majority of trials for renal disease have been in the early and mid-phases of development, with 56% of trials in Phase I-II, and 44% in Phase III-IV.The US has a substantial lead in the number of renal disease clinical trials globally. Germany leads the major European markets, while Japan has the top spot in Asia.Clinical trial activity in the renal disease space is dominated by completed trials. AbbVie has the highest number of completed clinical trials for renalKey Topics Covered: OVERVIEWKEY TAKEAWAYSDISEASE BACKGROUND Disease definitionPatient segmentationSymptomsRisk factorsDiagnosis TREATMENT Treatment of acute kidney injuryTreatment of chronic kidney disease EPIDEMIOLOGYMARKETED DRUGSPIPELINE DRUGSRECENT EVENTS AND ANALYST OPINION Veverimer for Renal Disease (December 8, 2020)Veverimer for Renal Disease (October 20, 2020)Farxiga for Renal Disease (August 30, 2020)Veverimer for Renal Disease (August 21, 2020)Farxiga for Renal Disease (July 28, 2020)Veverimer for Renal Disease (July 14, 2020)Farxiga for Renal Disease (March 30, 2020) KEY UPCOMING EVENTSKEY REGULATORY EVENTS New To The Review QueueFarxiga BTD Rests On Renal Outcomes Trial DAPA-CKDFDA Clears Medtronic's CRRT System For Pediatric Kidney Disease LICENSING AND ASSET ACQUISITION DEALS VTv Licenses Renal Disease Candidate To AnterisSpectrum Licenses CKD Therapy To UnicyciveAstraZeneca Likes Sound Of Silence's ScienceDeals Shaping The Medical Industry, February 2020 REVENUE OPPORTUNITYCLINICAL TRIAL LANDSCAPE Sponsors by statusSponsors by phaseRecent events BIBLIOGRAPHY Prescription information APPENDIXFor more information about this report visit https://www.researchandmarkets.com/r/ac07v5 CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
The "Prebiotic Ingredients Market Size, Share & Analysis, By Type, By Source (Roots, Vegetables, Grains, Others), By Bacterial Activity, By Functionality, By Application (Fortified Food & Beverages, Dietary Supplements, Animal Feed, Instant Formula And Others), And By Region, Forecast" report has been added to ResearchAndMarkets.com's offering.
Actor said she had hoped hypnotherapy would help her ‘stop being quite so petrified’
Climate group is calling on insurers to stop giving cover to fossil fuel projects
Brendan Rodgers warned his Leicester players not to be distracted from their task of qualifying for the Champions League by the FA Cup final after they tightened their grip on a top-four spot.
The stunt was part of a campaign against insuring fossil fuel mining.Activists from the Extinction Rebellion (XR) group unfurled banners with slogans such as "Climate Criminals" and dumped a load of blackened boulders in the road outside the Lloyd's building on Lime Street in the heart of the City of London.On Thursday (April 22), police arrested several XR activists after they shattered 19 windows at HSBC's headquarters in London's Canary Wharf.